Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.), Orlando, FL

Is Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location.

Does Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.) hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 4 licenses for this name and city, as of Nov 15, 2026: PH33404 for JUBILANT DRAXIMAGE INC. (dba Jubilant Radiopharma), ORLANDO, status Clear, PH33419 for JUBILANT DRAXIMAGE INC (dba Jubilant Radiopharma), ORLANDO, status Clear, PH31096 for JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma), ORLANDO, status Closed and PH31097 for JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma), ORLANDO, status Closed.

Has Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Aug 13, 2024) and 1 FMD-145 letter (Aug 14, 2024) for Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.). State board actions: no Florida Board of Pharmacy action on licenses PH33404, PH33419, PH31096 and PH31097 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Jubilant Draximage Radiopharmacies Inc.; Jubilant Radiopharma
Location
Orlando, FL
Type as FDA labels it
Not stated
FDA’s note
Nuclear Pharmacy
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Aug 14, 2024
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 6 observations
State board records
License found: PH33404, Clear; PH33419, Clear; PH31096, Closed; PH31097, Closed

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Jubilant Draximage Radiopharmacies Inc., (dba Jubilant Radiopharma), with 3 dated actions.

Document
Aug 14, 2024FMD-145 letterFMD-145 Letter Issued 08/14/2024Not linked by FDA
Aug 13, 2024State referral letterState Referral Letter Issued 08/13/2024FDA copy (archived)
Mar 13, 2024Form 483483 Issued 03/13/2024FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Jubilant DraxImage Radiopharmacies Inc., Orlando, FL (FEI number 3009339218), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 13, 2024Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30093392181232771

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 5, 2024 to Mar 13, 2024: 6 observations

Firm on the cover
Jubilant Draximage Radiopharmacies Inc. dba Jubilant Radiopharma, 4205 Vineland Rd Ste L13, Orlando, FL 32811-6601
Establishment type on the cover
Nuclear Pharmacy
FDA district office on the cover
555 Winderley Pl ace, Suite 200 Maitland, FL 32751
Matched to this page by
firm name, city and state on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Personnel were observed performing aseptic processing outside of an ISO 5 area.

Specifically on 03/06/24, during the production of Gozetotide (illucix) Cold Kit Lot# K-20240306-069 your firm's Pharmacy Manager was observed performing the following aseptic connections in the ISO-7 aseptic processing area: connecting the <Redacted B4> sterile <Redacted B4>to the Gallium Generator and connecting the Sterile <Redacted B4> to the Gallium _Generator. The following prescriptions were drawn from tlie cold kit and dispensed: RX <Redacted B4> 1394mCi and RX <Redacted B4> (25.49mCi).

Observation 2

Personnel were observed conducting aseptic manipulations where the movement of 11first air" in the ISO 5 area is blocked or dismpted.

Specifically, on 03/06/24, during the production of Gozetotide (Illucix) Cold Kit Lot# K-20240306-069 your firm's Pharmacy Manager was observed blocking first pass air in the IS0-5 <Redacted B4> flow hood. The following prescriptions were drawn from the cold kit and dispensed: RX <Redacted B4> (13.94 mCi) and RX <Redacted B4> (25.49 mCi).

Observation 3

Use of non-sterile disinfecting agents and cleaning pads in the ISO 5 area.

Specifically, your firm utilizes the following non-sterile cleaning agents <Redacted B4> <Redacted B4> and non-sterile <Redacted B4> within your <Redacted B4> ISO 5 <Redacted B4> flow hoods and <Redacted B4> ISO 5 BSCs.

Observation 4

Smoke studies were inadequately performed under dynamic conditions.

Specifically, on 03/16/24, inadequate smoke studies were observed within your firm's ISO 5 <Redacted B4> flow hood (video-SN:155019, 3:1 5). Turbulent and non-unidirectional airflow was observed during the operations. Ancillary supplies such as syringe containers and a labeling printer were observed blocking the grates and return vent within the hood allowing for air to recirculate.

Observation 5

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

Specifically, during the current FDA inspection, your firm determined that your media fill is not reflective of Gozetotide (Illucix) which is the most challenging drug product to produce because of the number of manipulations and poses the highest lisk to product sterility due to the transfer from the ISO <Redacted B4> flow hood to the Gallium Generator (requires aseptic connections) that is housed within the ISO 7 aseptic processmg area.

Observation 6

Inadequate routine environmental monitoring in the ISO 5 area and classified areas.

Specifically your firm was unable to determine that viable surface sampling of the ISO-5 environment (e.g., ISO-5 LAFHs and BSCs) occurs prior to cleaning operations.

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH33404PharmacyJUBILANT DRAXIMAGE INC. (dba Jubilant Radiopharma)ORLANDOClear
PH33419PharmacyJUBILANT DRAXIMAGE INC (dba Jubilant Radiopharma)ORLANDOClear
PH31096PharmacyJUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma)ORLANDOClosed
PH31097PharmacyJUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma)ORLANDOClosed

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.